Abstract
In patients with sepsis abnormalities in hemostatic variables indicating systemic activation of coagulation and early activation with subsequent inhibition of fibrinolysis, are common features [1-5]. The most important clinical manifestation of these processes is disseminated intravascular coagulation (DIC), which is characterized by generation and deposition of fibrin in the microvasculature with widespread microvascular thrombosis in various organ systems. The bipha- sic effect on the fibrinolytic system may result in impaired fibrin dissolution and aggravate the formation of microthrombi. There is evidence that DIC contributes to the development of (multiple) organ dysfunction and failure [3, 5]. In addition, depletion of coagulation proteins and platelets, mainly due to the extensive and ongoing coagulation activation, may induce severe bleeding complications [6]. The impressive extreme of the clinical spectrum of manifestations of DIC is purpura fulminans, which presents with hemorrhagic skin necrosis and peripheral gangrene and is most often seen in meningococcal sepsis [7].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Hesselvik JF, Blomback M, Brodin B et al (1989) Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 17:724–733
Voss R, Matthias FR, Borkowski G et al (1990) Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 75:99–105
Fourrier F, Chopin C, Goudemand J et al (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816–823
Lorente JA, Garcia-Frade LJ, Landin L et al (1993) Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536–1542
Kidokoro A, Iba T, Fukunaga M et al (1996) Alterations in coagulation and fibrinolysis during sepsis. Shock 5:223–228
Levi M, ten Cate H, van der Poll T et al (1993) Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 270:975–979
Fijnvandraat K, Derkx B, Peters M et al (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15–20
Ziegler EJ, Fisher CJ, Sprung CL et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin. N Engl J Med 324: 429–436
Greenman RL, Schein RMH, Martin MA et al (1991) A controlled clinical trial of E5 Murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097–1102
Fisher CJ, Dhainaut JFA, Opal SM et al (1994) Recombinant human Interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271:1836–1843
Abraham E, Wunderink R, Silverman H et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. JAMA 273:934–941
Bone RC, Baik RA, Fein AM et al (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23:994–1005
Cohen J, Carlet J, Intersept study group (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 24:1431–1440
Rangel-Frausto MS, Pittet D, Costigan M et al (1995) The natural history of the systemic inflanmiatory response syndrome (SIRS). A prospective study. JAMA 273:117–123
Levi M, ten Cate H, Bauer KA et al (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93:114–120
Biemond BJ, ten Cate H, Levi M et al (1995) Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VlWIIa. Thromb Haemost 73:223–230
Pixley RA, DeLa Cadena R, Page JD et al (1993) The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 91: 61–68
Ten Cate H, Brandjes DPM, Wolters HJ et al (1993) Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. New Horizons 1:312–323
Gregory SA, Morrissey JH, Edgington TS (1989) Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 9:2752–2755
0sterud B, Flaegstad T (1983) Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 49:5–7
Moore KL, Andreoli SP, Esmon NL et al (1987) Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 79:124–130
Colucci M, Balconi G, Lorenzet R et al (1983) Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 71:1893–1896
Furie B, Furie BC (1992) Molecular and cellular biology of blood coagulation. N Engl J Med 326:800–806
Wada H, Minamikawa K, Wakita Y et al (1993) Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 43:190–194
Kobayashi M, Shimada K, Ozawa T (1990) Human recombinant interleukin 1-beta and tumor necrosis factor alfa-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 144:383–390
Abe H, Okajima K, Okabe H et al (1994) Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J Lab Clin Med 123:874–881
Alcaraz A, España F, Sánchez-Cuenca J et al (1995) Activation of the protein C pathway in acute sepsis. Thromb Res 79:83–93
Rapaport SI (1991) The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 66:6–15
Girard TJ, Warren LA, Novotny WF et al (1989) Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338:518–520
Taylor Jr FB, Emerson Jr TE, Jordan R et al (1988) Antithrombin-EI prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26:227–235
Taylor Jr FB, Chang A, Esmon CT et al (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in baboons. J Clin Invest 79:918–925
Creasey AA, Chang ACK, Feigen L et al (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J CHn Invest 91:2850–2860
Carr C, Bild GS, Chang ACK et al (1995) Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ Shock 44:126–137
Taylor F, Chang A, Ferrel G et al (1991) C4b-binding protein exacerbates the host response to Escherichia coli. Blood 78:357–363
Philippe J, Offner F, Declerck PJ et al (1991) Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 65:291–295
Jansen PM, Pixley RA, Brouwer M et al (1996) Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interieukin-6 and neutrophil elastase. Blood 87:2337–2344
Sprengers ED, Kluft C (1987) Plasminogen activator inhibitors. Blood 62:381–387
Emeis JJ, Kooistra T (1986) Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 163: 1260–1266
Hanss M, Collen D (1987) Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 109:97–104
Colluci M, Paramo JA, Collen D (1985) Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75:818–824
Van Deventer SJH, Buller HR, Ten Cate JW et al (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76:2520–2526
Van der Poll T, Levi M, van Deventer SJH et al (1994) Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83:446–451
Van der Poll T, Levi M, Hack CE et al (1994) Elimination of Interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179:1253–1259
Suffredini AF, Harpel PC, Parrillo JE (1989) Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165–1172
Biemond BJ, Levi M, ten Cate H et al (1995) Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokines and coagulation cascades. Clin Science 88:587–594
De Boer JP, Creasy AA, Chang A et al (1993) Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 39:59–67
Hack CE, Thijs LG (1991) The orchestra of mediators in the pathogenesis of septic shock: A review. In: Vincent JL (ed) Update in Intensive Care and Emergency Medicine. Springer, New York, pp 232–246
Redl H, Schiag G, Bahrami S et al (1991) Plasma neutrophil-activating peptide-1/ Interleukin-8 and neutrophil elastase in a primate bacteremia model. J Infect Dis 164:383–388
Bevilacqua MP, Pober JS, Majeau GR et al (1984) Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160:618–623
Conway EM, Back R, Rosenberg RD et al (1989) Tumor necrosis factor enhances expression of tissue factor in RNA in endothehal cells. Thromb Res 53:231–241
Conkling PR, Greenberg CS, Weinberg JB (1988) Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 72:128–133
Nawroth PP, Handley DA, Esmon CT et al (1986) Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 83: 3460–3464
Conway EM, Rosenberg RD (1988) Tumor necrosis factor suppresses transcription of thrombomodulin gene in endothelial cells. Mol Cell Biol 8:5588–5592
Schleef RR, Bevilacqua MP, Sawdey M et al (1988) Cytokine activation of vascular endothelium: effects on tissue-type plasminogen activator and type I plasminogen activator inhibitor. J Biol Chem 263:5797–5803
Van der Poll T, Buller HR, ten Cate H et al (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622–1627
Van der Poll T, Levi M, Buller HR et al (1991) Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174:729–732
Bauer KA, ten Cate H, Barzegar S et al (1989) Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 74:165–172
Van Hinsbergh VWM, Bauer KA, Kooistra T et al (1990) Progress of fibrinolysis during tumor necrosis factor infusion in humans, concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 76: 2284–2289
Jansen PM, Boermeester MA, Fischer E et al (1995) Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: Studies in nonhuman primates after interleukin-la administration and during lethal bacteremia. Blood 86:1027–1034
Boermeester MA, van Leeuwen PAM, Coyle SM et al (1995) Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg 130:739–748
Giles AR, Nesheim ME, Herring SW et al (1990) The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 63:476–481
Mesters RM, Mannuccio PM, Coppola R et al (1996) Factor Vila and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88:881–886
Mesters RM, Florke N, Ostermann et al (1996) Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 75:902–907
Leclerc F, Hazelzet J, Jude B et al (1992) Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 18:202–205
Thijs LG, de Boer JP, de Groot MCM et al (1993) Coagulation disorders in septic shock. Intensive CareMed l9:S8-S15
Takahashi H, Tatewaki W, Wada K et al (1990) Thrombin versus plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Hematol 33:90–95
Hesselvik JF, Malm J, Dahlback B et al (1991) Protein C, Protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 65:126–129
Wuillemin WA, Fijnvandraat K, Derkx BHF et al (1995) Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 74:1436–1441
Brandtzaeg P, Sandset PM, Jo0 GB et al (1989) The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 55:459–470
Warr TA, Rao LVM, Rapaport SI (1989) Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 74:994–998
Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ et al (1988) Quantification of plasma factor Xlla-Cl-inhibitor and kallikrein-Cl-inhibitor complexes in sepsis. Blood 72:1841–1848
Kaufman N, Page JD, Pixley RA et al (1991) oc2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 77:2660–2667
Pralong G, Calandra T, Glauser MP et al (1989) Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 61:459–462
Gando S, Kameue T, Nanzaki S et al (1996) Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 75: 224–228
Kruithof EKO, Calandra T, Pralong G et al (1993) Evolution of plasminogen activator inhibitor type I in patients with septic shock — correlation with cytokine concentrations. Fibrinolysis 7:117–121
Brandtzaeg P, Jo0 GB, Bmsletto B et al (1990) Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57:271–278
Okajima K, Yang W-P, Okabe H et al (1991) Role of leukocytes in the activation of intravascular coagulation in patients with septicemia. Am J Hemat 36:265–271
Ono S, Mochizuki H, Tamakuma S (1996) A clinical study on the significance of platelet-acti- vating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Am J Surg 171:409–415
Idell S, James KK, Levin EG et al (1989) Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 84:695–705
Bertozzi P, Astedt B, Zenzius L et al (1990) Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 322:890–897
Tanaka T, Tsujinaka T, Kambayashi J-I et al (1990) The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model. Thromb Res 60:321–330
Coalson JJ, Benjamin B, Archer LT et al (1978) Prolonged shock in the baboon subjected to infusion of E. coH endotoxin. Circ Shock 5:423–437
Emerson TE Jr, Fournel MA, Redens TB et al (1989) Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 87:27S-33S
Blauhut B, Kramar H, Vinazzer H et al (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39:81–89
Maki M, Terao T, Ikenoue T et al (1987) Clinical evaluation of antithrombin EI concentrate and BI 6.013 for disseminated intravascular coagulation in obstetrics. Gynecol Obstet Invest 23:230–240
Fourrier F, Chopin C, Huart JJ et al (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882–888
Yamauchi T, Umed F, Inoguche T (1991) Antithrombin EI stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Comm 163:1404–1411
Okajima K, Imamura H, Koga S et al (1990) Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hemat 33:277–278
Salat C, Boekstegers P, Holler E et al (1996) Hemostatic parameters in sepsis patients treated with anti-TNFa-monoclonal antibodies. Shock 6:233–237
Taylor Jr FB, Chang A, Ruf W et al (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127–134
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Italia, Milano
About this paper
Cite this paper
Thijs, L.G. (1998). Disturbances and Modulators of Coagulation and Fibrinolysis in Sepsis. In: Baue, A.E., Berlot, G., Gullo, A. (eds) Sepsis and Organ Dysfunction. Springer, Milano. https://doi.org/10.1007/978-88-470-2271-3_10
Download citation
DOI: https://doi.org/10.1007/978-88-470-2271-3_10
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0297-5
Online ISBN: 978-88-470-2271-3
eBook Packages: Springer Book Archive